viewXPhyto Therapeutics Corp.

XPhyto Therapeutics starts CBD-infused beverage research with leading German institution

It is researching infused beverages with the Technical University of Munich, School of Life Sciences Weihenstephan

XPhyto Therapeutics Corp. -
Weihenstephan is known for its state-run brewery, the oldest still in operation in the world

XPhyto Therapeutics Corp (CSE:XPHY) is kicking off its research into cannabis-infused beverages via an exclusive strategic partnership with a leading German research centre. 

The cannabis company said Tuesday that its German subsidiary Bunker Pflanzenextrakte GmbH has started work on research and development of cannabis-focused beverages with the chair of the brewing and beverage technology at the Technical University of Munich ("TUM"), School of Life Sciences Weihenstephan. 

Vancouver-based XPhyto recently signed a supply, import and distribution agreement for cannabis extracts with an undisclosed cultivator to support its expanding German medicinal marijuana business. 

READ: XPhyto Therapeutics brings in C$2M from placing for European imports business

Weihenstephan is known for the Benedictine Weihenstephan Abbey, which is home to the oldest still-operating brewery in the world and now run by a state-owned firm, Bavarian State Brewery Weihenstephan. 

The town is also home to the International Beverage Research Centre (iGZW), an interdisciplinary R&D facility that looks at the entire drink design process from molecular biology through to the final product. The institution has a specific focus on flavor-process-engineering, raw material and product design, food safety, and relevant legislative issues, such as EU designated “novel foods,” according to XPhyto. 

IGZW’s group leader Dr-Ing. Marrtina Gastl said the group was “pleased” to be working with XPhyto on cannabis-based beverages that have “great potential to create opportunities for product innovations” in an increasingly large global market. 

Globally-recognized partner

Hugh Rogers, XPhyto’s CEO, said the firm was “extremely pleased” to collaborate with a globally recognized partner for the research and development of cannabis-based products and beverages.  

“Our recently signed and announced supply, import and distribution agreement for cannabis extracts and isolates with one of the highest quality and largest cannabis cultivators in the world, will ensure the supply of necessary ingredients for all the products developed," said Rogers in a statement. 

"Given that XPhyto has been approached by beverage companies in Europe and North America with interest in potential collaboration for the development of cannabis-infused products at Weihenstephan, we are confident that we are on the right track with this exclusive strategic partnership." 

The firm recently brought in C$2 million to support its European imports business.

Contact Angela at [email protected]

Follow her on Twittter @AHarmantas

Quick facts: XPhyto Therapeutics Corp.

Price: 2.26 CAD

Market: CSE
Market Cap: $137 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...


XPhyto Therapeutics continues to move toward commercialization of their...

XPhyto Therapeutics (CSE: XPHY- OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide an update on their plans to go to market in Europe with their testing program for the COVID-19 Rogers talks about where that program is AT and also about their drug delivery platform...

on 4/11/20

2 min read